Balanced news tone
News Sentiment
PCSA sentiment intelligence
Processa Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
52 relevant articles
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+6.9% over one week, +9.0% over four weeks, trend inactive, and below fair value.
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
83/100 classification
One-week reaction
6.9%
Price confirming higher
Trend fit
Trend inactive
9.0% over four weeks
Fair value
-95.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
38
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Benzinga España
Direct company coverage
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights
This report provides a stock analysis for Processa Pharma (PCSA), a clinical-stage biopharmaceutical company focusing on Next Generation Chemotherapy oncology drug products. It covers the company's general information, how it's graded based on various financial metrics, peer comp
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 07:11
- Source
- Benzinga España
Moomoo
Direct company coverage
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL
This article is a statement of changes in beneficial ownership of securities for Officer SKIBSTED RUSSELL at Processa Pharmaceuticals. It indicates a filing of Form Type 4, which is used to report changes in ownership of company stock by insiders. The article details the specific
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 19:12
- Source
- Moomoo
Moomoo
Direct company coverage
PROCESSA PHARMACEUTICALS INC. For: Jun 03 Filed: Jun 06
This document, filed by PROCESSA PHARMACEUTICALS INC. on June 6 for the date June 3, is a statement of changes in beneficial ownership of securities. It specifically details changes for Officer Ng George K.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 19:12
- Source
- Moomoo
Moomoo
Direct company coverage
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lin Patrick
This document reports a statement of changes in beneficial ownership of securities for Officer Lin Patrick of Processa Pharmaceuticals. It is filed as a Form 4, indicating transactions related to his holdings in the company.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 18:12
- Source
- Moomoo
Stock Titan
Direct company coverage
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market
Processa Pharmaceuticals (PCSA) director David Young purchased 2,531 shares of common stock at $1.93 per share in an open-market transaction on June 30, 2026. This acquisition increases his direct holdings to 21,729 shares. Young also reported indirect ownership through several e
- Tone
- Positive 69/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 04:39
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com
Processa Pharmaceuticals CEO George Ng recently acquired 3,057 shares of the company's common stock for $5,900. This transaction increases his direct holdings to 15,492 shares, in addition to indirect holdings. The purchase occurred while PCSA stock is trading near its 52-week lo
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 01 Jul 2026 20:39
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy
Processa Pharmaceuticals (PCSA) CEO George K. Ng purchased 3,057 shares of Common Stock in an open-market transaction at $1.93 per share on July 1, 2026. Following this transaction, Ng directly owns 15,492 shares, with additional indirect holdings through related entities. The pu
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 01 Jul 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy
Processa Pharmaceuticals' Chief Administrative Officer Guy Wendy recently purchased 2,436 shares of common stock at $1.93 per share in an open-market transaction. Following this purchase, Wendy directly holds 14,394 shares and indirectly owns 333 shares through CorLyst, LLC. This
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 01 Jul 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy
Processa Pharmaceuticals, Inc.'s Chief Financial Officer, Russell Skibsted, purchased 3,277 shares of common stock at $1.93 per share in an open-market transaction on June 30, 2026. This purchase increased his direct holdings to 16,689 shares. The transaction was filed in a Form
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 01 Jul 2026 20:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Processa (PCSA) strategy chief adds 2,106 shares in insider buy
Patrick Lin, Chief Business-Strategy Officer at Processa Pharmaceuticals, Inc. (PCSA), made an open-market purchase of 2,106 common shares at $1.93 per share on June 30, 2026. This transaction increased his direct holdings to 13,113 shares, in addition to 1,740 shares held indire
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 01 Jul 2026 20:39
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com
This article from Investing.com announces a Form 4 filing for Processa Pharmaceuticals Inc. It provides the date of the filing, July 1st, and is very concise in its content. The remainder of the page is filled with financial market data, indices, commodity prices, and other news
- Tone
- Neutral 50/100
- Event
- Macro sensitivity
- Published
- 01 Jul 2026 20:39
- Source
- Investing.com Canada
Moomoo
Direct company coverage
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Yorke Justin W
This document is a Form 4 statement of changes in beneficial ownership of securities for Justin W. Yorke, a director of Processa Pharmaceuticals. It indicates potential transactions or changes in his holdings of the company's stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 18:09
- Source
- Moomoo
TradingView
Direct company coverage
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings
This page provides access to Processa Pharmaceuticals, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details past earnings reports, highlighting net losses, cash shortfalls, and the need for additional funding, while also noting pipeline ad
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 09:12
- Source
- TradingView
Stock Titan
Direct company coverage
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting
Processa Pharmaceuticals director Neal James R received 203 shares of common stock from the vesting of a time-based service award on June 26, 2026. This transaction increased his direct holdings of common stock to 1,021 shares, while he still holds 5,249 shares of restricted stoc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 04:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity
Processa Pharmaceuticals director Geraldine Pannu reported an insider transaction involving the exercise of a derivative award for 203 shares of Common Stock on June 26, 2026, at an exercise price of $0.00. This transaction increased her direct holdings of Common Stock to 2,391 s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 04:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award
Processa Pharmaceuticals director Justin W. Yorke reported the vesting of a 203-share restricted stock award on June 26, 2026, receiving common stock at $0.00 per share. This transaction increases his direct holdings to 353 common shares, with additional indirect holdings and 5,2
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 04:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award
Processa Pharmaceuticals director Baluch Khoso received 203 shares of common stock from a time-based service award, converting restricted stock at an exercise price of $0.00 per share. This transaction on June 26, 2026, was a routine equity compensation event rather than a market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 04:09
- Source
- Stock Titan
TradingView
Direct company coverage
Price to earnings forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA
The article displays the "Price to earnings forward" metric for Processa Pharmaceuticals, Inc. (NASDAQ:PCSA). It is presented within the context of TradingView's financial data interface, with a placeholder indicating "No trades" and "Market closed" at the time of viewing.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 01:15
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA
This article provides financial information for Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), specifically focusing on its forward price-to-sales ratio. The content appears to be a snapshot from a financial platform like TradingView, displaying basic company information and fina
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:09
- Source
- TradingView
TradingView
Direct company coverage
Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA)
This article provides an overview of Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, upcoming earnings reports, and an analysis of its volatility and dividend
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 25 Jun 2026 14:40
- Source
- TradingView
Quiver Quantitative
Direct company coverage
PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation
This article provides detailed executive compensation information for Processa Pharmaceuticals, Inc. (PCSA), including salary, bonus, stock/option awards, and total compensation for named executives. It also offers an overview of the company, its financial data, and various analy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 17:09
- Source
- Quiver Quantitative
Moomoo
Direct company coverage
Processa Pharmaceuticals | DEF 14A: Definitive information statements
This article mentions that Processa Pharmaceuticals has filed a DEF 14A, which is a definitive information statement. Further details about the content of this filing are not provided in the snippet.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 14:09
- Source
- Moomoo
Stock Titan
Direct company coverage
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay
Processa Pharmaceuticals will hold its 2026 annual shareholder meeting on July 30, 2026, where shareholders will vote on key proposals including the election of six directors, an increase in the 2019 Omnibus Incentive Plan share reserve by 200,000 shares, and the ratification of
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:40
- Source
- Stock Titan
TradingKey
Direct company coverage
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Processa Pharmaceuticals Inc (PCSA) currently has no earnings forecast score available from TradingKey, which contrasts with the Biotechnology & Medical Research industry's average score of 8.13. Analysts forecast a price target of $1.00 for PCSA, with a previous quarter's EPS of
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 18 Jun 2026 09:40
- Source
- TradingKey
TradingKey
Direct company coverage
Processa Pharmaceuticals Inc
This article provides a brief overview of Processa Pharmaceuticals Inc (PCSA), including its current stock price and market capitalization. It indicates that relevant revenue breakdown data by business and region have not yet been disclosed by the company. The page appears to be
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 05:39
- Source
- TradingKey
TradingKey
Direct company coverage
Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a timeline of dividend payouts and stock splits for Processa Pharmaceuticals Inc (PCSA). It indicates that the company has distributed no dividends over the past five years and details several merger-related stock splits with specific dates and ratios. The cu
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 05:39
- Source
- TradingKey
TradingKey
Direct company coverage
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Processa Pharmaceuticals Inc (PCSA), including major individual and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity wit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 05:39
- Source
- TradingKey
TradingKey
Direct company coverage
Processa Pharmaceuticals Inc (PCSA) Institutional Confidence
This article provides an "Institutional Confidence" score for Processa Pharmaceuticals Inc (PCSA), noting a score of 3.00 as of June 18, 2026. It details key institutional shareholders and their recent activity, including HX Entertainment Ltd with a significant ownership and incr
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 23:09
- Source
- TradingKey